Peer-reviewed veterinary case report
Gemcitabine treatment tested in dogs with cancer
By Kosarek, Carrie E et al.·Published in Journal of veterinary internal medicine·2005·Department of Veterinary Clinical Sciences and Veterinary Teaching Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies.
- Species:
- dog
Plain-English summary
Nineteen dogs with cancer were treated with a chemotherapy drug called gemcitabine, given through an IV every two weeks. While no complete or partial remissions were seen initially, two dogs showed some positive responses during a longer evaluation period. The treatment was generally safe, with minimal side effects, although one dog experienced unexplained bleeding in the eye. Overall, gemcitabine appears to be a promising option for dogs with cancer, as it can be administered with acceptable toxicity levels.
People also search for: dog cancer treatment options · gemcitabine for dogs · side effects of chemotherapy in dogs
Abstract
We conducted a clinical evaluation of gemcitabine in 19 dogs with spontaneously occurring malignancies. The principal objectives of this study were to characterize toxicity and seek preliminary evidence of antitumor activity of gemcitabine administered every 2 weeks (biweekly) as a 30-minute IV infusion. A total of 64 doses, ranging from 300 mg/m2 to 675 mg/m2, were administered during the initial 8-week evaluation period, and an additional 131 doses were administered during the extended evaluation period. The total cumulative dose for the 10 dogs receiving gemcitabine in the extended evaluation period ranged from 1,500 mg/m2 to 24,300 mg/m2. Clinical evidence of toxicity was minimal. Cumulative myelosuppression was not apparent. Unexplained retinal hemorrhages occurred in 1 dog. No complete or partial remissions were observed during the initial evaluation period; however, objective responses were observed in 2 dogs during the extended evaluation period. Gemcitabine is a promising new chemotherapeutic agent that can be used safely in dogs with cancer. Biweekly administration of doses of 675 mg/m2 IV results in minimal and acceptable toxicity.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15715052/